Blood component transfusion is a frequently prescribed intervention in healthcare that depends on the availability of a limited and expensive resource. The transfusion of blood products may be life-saving, but it is not without risk. Society guidelines and clinical trials guide transfusion decisions regarding transfusion thresholds, as well as the appropriateness of prophylactic v. therapeutic transfusion strategies. This review provides a practical and evidence-informed approach to the transfusion of red blood cells and platelets in commonly encountered clinical settings.
CME
The donor blood supply of any country is a limited and carefully regulated resource. With only 1% of South Africans being active blood donors, an evidence-informed approach to blood transfusion helps to ensure that blood products are given to individuals who may derive benefit from their administration. [1] While blood transfusion is relatively safe, the potential for serious adverse events should be considered whenever a transfusion is ordered ( Table 1 ). The annual Serious Hazards of Transfusion (SHOT) report details a risk of serious harm associated with transfusion as ~1 in 21 000 and a risk of death as 1 in 117 000 components issued in the UK. [2] Blood transfusion should ideally be prescribed in the clinical setting where evidence supports efficacy, while balancing potential harm. Moreover, the indications for transfusion should be recognised promptly to reduce the sequelae of transfusion delays. Multiple trials, reviews and guidelines serve to inform appropriate transfusion thresholds in commonly encountered clinical contexts.
Red blood cell transfusion What is the ideal red blood cell transfusion threshold?
The default red blood cell transfusion (haemoglobin (Hb)) threshold had been 10.0 g/dL for >40 years, until a landmark clinical trial demonstrated that this liberal transfusion practice was largely unnecessary in the setting of critical care. [3] Clinical trials have likewise demonstrated the safety of a restrictive transfusion strategy in a variety of clinical settings. Despite these trials, the 'optimal' red cell transfusion threshold is unknown and reflects our rudimentary understanding of short-and long-term physiological adaptations to anaemia and an individual's dynamic oxygen delivery needs. Despite these limitations, current transfusion thresholds identified through clinical trials provide a framework with which to approach patients.
Non-bleeding hospitalised adult patients
The Transfusion Requirements in Critical Care (TRICC) trial randomised non-bleeding euvolaemic critically ill patients to a 'restrictive' red cell transfusion strategy (threshold of 7.0 g/dL) v. a 'liberal' transfusion strategy (threshold of 10.0 g/dL). [3] This landmark trial published in 1999 showed for the first time that a restrictive transfusion strategy was safe and may even be beneficial in specific patient populations. A restrictive transfusion threshold resulted in a 54% decrease in the number of red cell transfusions administered. Furthermore, 33% of patients in the restrictive arm were not transfused compared with 0% of the liberal arm. Subsequently, studies have been conducted in various patient populations, including orthopaedic and cardiac surgery, sepsis and haematopoietic cell transplantation (HCT). A Cochrane systematic review and meta-analysis recently evaluated clinical outcomes associated with restrictive (7.0 -9.0 g/dL) Table 1 . Selected risks associated with blood product transfusion [17] Risk* Blood product transfusion 1 in 13
Red cell sensitisation (increased risk for haemolytic transfusion reaction and haemolytic disease of the newborn) 1 in 20
Febrile non-haemolytic transfusion reaction per pool of platelets 1 in 100
Transfusion-associated circulatory overload 1 in 100 Urticaria 1 in 300
Febrile non-haemolytic transfusion reaction per red blood cell unit transfused 1 in 7 000
Delayed haemolytic transfusion reaction 1 in 10 000
Transfusion-related acute lung injury 1 in 40 000
Serious allergic reaction 1 in 13 000 000
Hepatitis C virus infection 1 in 7 500 000
Hepatitis B virus infection 1 in 21 000 000 HIV infection *Risk estimates are likely to have wide confidence intervals. CME v. liberal (10.0 g/dL) transfusion thresholds in 12 587 hospitalised patients enrolled in 31 randomised trials. [4] Restrictive transfusion strategies reduced the relative risk of receiving a blood transfusion by 43% and did not significantly impact relevant clinical outcomes. Uncertainty remains surrounding the optimal transfusion threshold in acute coronary syndromes (ACS) and traumatic brain injury (TBI); both are being evaluated in ongoing clinical trials (Myocardial Ischemia and Transfusion (MINT) trial for ACS (NCT02981407), and the HEMOglobin Transfusion Threshold in Traumatic brain Injury OptimizatioN (HEMOTION) trial for TBI (NCT03260478)). Based on the data described above, a transfusion threshold of 7.0 g/dL is recommended for haemodynamically stable non-bleeding hospitalised patients, including those who are critically ill ( Table 2 ). Most professional guidelines recommend that blood transfusions be used in symptomatic anaemia (chest pain, orthostatic hypotension, tachycardia unresponsive to fluid resuscitation or congestive heart failure) provided the Hb is <10.0 g/dL. [4] Despite a lack of randomised clinical trial data to support the adoption of a higher threshold, the American Association of Blood Banks (AABB) recommends a transfusion threshold of 8.0 g/dL in patients undergoing orthopaedic or cardiac surgery, and for those with pre-existing cardiovascular disease. [5] The recently published Transfusion Requirements in Cardiac Surgery (TRICS) III trial, demonstrating non-inferiority of a restrictive transfusion threshold of 7.5 g/dL in cardiac surgery, corroborates that a lower threshold is well tolerated in cardiac surgery patients. [6] In the setting of ACS, society guidelines support variable transfusion thresholds of >8.0 -10.0 g/dL, while we await randomised data to better inform transfusion decisions in this patient population ( Table 2 ). [5, 7] Bleeding hospitalised adult patients In a single, large randomised controlled trial (RCT) of patients with gastrointestinal (GI) bleeding, a restrictive transfusion threshold of 7.0 g/dL (v. 9.0 g/dL) was associated with fewer red cell units transfused, less re-bleeding and increased survival at 30 days. [4] As such, haemodynamically stable patients with GI bleeding should be managed with a transfusion threshold of 7.0 g/dL ( Table 2 ). In the context of massive transfusion protocols (MTPs) designed to provide optimal red blood cell (RBC):plasma:platelet ratios, the ideal transfusion threshold in massive transfusion is unknown. In the absence of randomised trials, maintaining a nadir Hb >8.0 g/dL is pragmatic; however, transfusion decisions should consider the clinical context and be modified by laboratory testing.
Ambulatory patients with chronic transfusion requirements
There are limited randomised clinical trial data to guide outpatient transfusion thresholds. Two ongoing prospective pilot studies (NCT 02099669; ISRCTN 26088319) are evaluating optimal transfusion thresholds in myelodysplastic syndrome (MDS). These studies will evaluate the impact of liberal (Hb target >11.0 g/dL) v. restrictive (Hb target >8.5 g/dL) transfusion strategies on quality of life. Given the established safety of restrictive transfusion strategies in critically ill and hospitalised patients, and with the added concerns for increased risks of allo-immunisation and iron overload due to chronic transfusion, consensus recommendations suggest a restrictive transfusion threshold (typically 8.0 -9.0 g/dL) in most ambulatory patients with acquired marrow failure syndromes ( Table 2 ).
Platelet transfusion Should platelets be transfused prophylactically, and at what platelet count threshold?
Similar to RBC transfusion decisions, the appropriateness of platelet transfusion must be considered in each specific clinical setting. Prophylactic transfusion strategies (i.e. transfusion at a pre-specified platelet count threshold to reduce the risk of bleeding) are important in the supportive care of many patients, but evolving evidence suggests that therapeutic transfusion strategies (i.e. at the first sign of bleeding) may be appropriate in specific clinical settings.
Therapy-induced reversible myelosuppression
Prophylactic platelet transfusion strategies at platelet count thresholds of <10 × 10 9 /L in patients with haematological malignancies who have therapy-related thrombocytopenia have been shown to primarily reduce the risk of World Health Organization (WHO) grade 2 bleeding (Tables 3 and 4 ). [8] These results have been extrapolated to formulate recommendations in other settings of therapy-related hypoproliferative marrow states. [9] [10] [11] It is also recommended that prophylactic platelet transfusion (threshold of <10 × 10 9 /L) be used for patients undergoing allogeneic HCT. [8] In the setting of autologous HCT, subgroup analysis of two RCTs demonstrates that therapeutic (compared with prophylactic) platelet transfusion strategies reduce platelet transfusions without impacting rates of major bleeding (WHO grade 3 or 4 bleeding; Table 3 ). Given these data, several society guidelines currently suggest a therapeutic platelet transfusion strategy for patients undergoing autologous HCT (Table 4 ). [9, 11] This approach requires inpatient-based monitoring with platelet transfusion at the first sign of clinically significant bleeding (WHO grade 2 or higher bleeding). As the aforementioned clinical trials have demonstrated that many of these patients continue to experience bleeding complications despite platelet transfusion, [19] ) and for those who are potential candidates for allogeneic haematopoietic cell transplantation. § Platelet transfusions should only be used for life-threatening bleeding. ¶ Inserted with bedside ultrasound and by experienced personnel. Avoid non-compressible vessels if platelets are <50 × 10 9 /L. Choosing a compressible site is preferable to a prophylactic platelet transfusion. CME two ongoing clinical trials, TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia (TREATT; NCT03136445) and Platelet Transfusion Requirements in Hematopoietic Transplantation (PATH; NCT02650791), evaluate the prophylactic use of tranexamic acid to prevent bleeding in patients with severe thrombocytopenia and haematological malignancies.
Critically ill patients
Despite a lack of high-quality prospective data, prophylactic platelet transfusions at platelet thresholds of <10 × 10 9 /L are recommended in the setting of critical illness with reversible marrow failure ( Table 4 ). [9] Irreversible bone marrow failure (congenital or acquired) A recent systematic review identified one small RCT (N=9) of therapeutic platelet transfusion strategies in MDS that was terminated early due to poor recruitment. [12] The paucity of data to inform decision-making, highlights the need for trials in this clinical context. A single retrospective study in severe aplastic anaemia evaluated outcomes associated with a prophylactic transfusion strategy (platelet threshold of ≤5 × 10 9 /L). All deaths from haemorrhage were associated with preceding platelet alloimmunisation or palliation, and only three episodes of non-fatal major bleeding occurred. [13] Due to the risks of platelet alloimmunisation, and the economic burden associated with a chronic transfusion programme, several international guidelines recommend a therapeutic transfusion strategy unless there is evidence of recurrent bleeding (WHO grade 2 or higher (Tables 3 and 4) ). [9, 11] A caveat to this would be for potential candidates of allogeneic HCT, where a prophylactic transfusion strategy (platelet threshold of <10 × 10 9 /L) is reasonable.
Immune thrombocytopenia and thrombotic thrombocytopenic purpura
Prophylactic transfusion strategies are not recommended in the routine management of immune thrombocytopenia (ITP) owing to the ineffectiveness of platelet transfusion in this setting, as well as the potential of exacerbating the underlying prothrombotic disease state. In ITP, platelet transfusion should only be given therapeutically in serious bleeding situations or prior to urgent surgical/procedural interventions, perhaps also with the co-administration of intravenous immunoglobulin to reduce platelet consumption. In the absence of lifethreatening bleeding, prophylactic platelet transfusions are likewise contraindicated in the setting of thrombotic thrombocytopenic purpura (TTP), where studies have indicated an increase in mortality associated with platelet transfusions. [9] Before procedures or surgery The need for prophylactic transfusion strategies prior to surgery or procedures has not been sufficiently evaluated in RCTs. [14] Existing recommendations are derived from observational studies that describe clinical outcomes following platelet transfusion for specific platelet thresholds (Table 3 ). [15] What is the appropriate dose of prophylactic platelet transfusion?
A large clinical trial (N=1 272), the Prophylactic Platelet Dose (PLADO) trial, demonstrated that in patients with hypoproliferative marrow disorders, low-dose platelet transfusions prescribed prophylactically at platelet concentrations of <10 × 10 9 /L were as effective as higher doses of platelets in preventing WHO grade 2 or higher bleeding complications. [16] Accordingly, in non-bleeding patients, if a prophylactic platelet transfusion strategy is adopted, guidelines recommend transfusion with one adult dose of plate lets. [9, 10] In the absence of consumption or destruction, each platelet dose should increase an adult patient's platelet count by 15 -25 × 10 9 /L when measured at 1 hour. If a platelet increment of <10 × 10 9 /L is achieved post-transfusion on more than one occasion, platelet refractoriness and the need for consultation with transfusion medicine experts are suggested. [17] Are transfusion 'thresholds' the best determinant of the need for transfusion?
While the adoption of specific transfusion thresholds can prevent overutilisation of blood products, it is equally important to acknowledge the limitations of 'threshold' decisions in clinical practice. Clinical scenarios are varied and require a nuanced interpretation of the risks and benefits of transfusion. This notion is highlighted in the setting of anaemia of chronic disease. This condition is often viewed as deleterious due to the assumed reduction in oxygen delivery to tissues, as well as the association of anaemia with poor prognosis in many clinical disorders, but these notions are debatable. Firstly, the ability of the body to compensate for the often mild to moderate anaemia (Hb >8.0 g/dL) observed in chronic disease through both increased oxygen unloading and increased oxygen tissue extraction is typically sufficient to maintain adequate oxygen delivery. [18] Secondly, while anaemia is associated with increased mortality in many diseases, it is not proof of causation. Several studies have shown that when disease severity and inflammation are accounted for, anaemia of chronic disease is no longer prognostic for mortality. Moreover, the development of anaemia in response to systemic disease is evolutionally conserved in animals with closed circulatory systems and suggests an adaptive response. [18] As such, not all anaemias are equal, and an understanding of the aetiology and physiological impact of anaemia is fundamental in determining transfusion thresholds for individual patients. Likewise, the decision to transfuse platelets based solely on a number may fail to consider the presence of platelet dysfunction (either congenital or acquired), concomitant coagulopathy, and the potential consequence of bleeding, should it occur.
Conclusions
The transfusion of blood products is one of the most routine interventions in healthcare. As the provision of blood products relies on a limited resource, transfusion practices need to be carefully scrutinised. A one-size-fits-all approach in clinical practice has appropriately fallen by the wayside, and, as this review demonstrates, the decision to transfuse blood products is no exception. While the referenced transfusion thresholds serve as a general guide that reflects the best available data, each patient, their comorbidities, preferences, as well as the clinical settings, should be considered prior to the prescription of a blood product transfusion.
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